Experimental · 5/10
P21 (P021)
P21 (P021) is a CNTF-derived peptidomimetic that crosses the blood-brain barrier and, in mice, raises BDNF, lifts hippocampal neurogenesis, and lowers tau pathology in Alzheimer's models. The catch is total. There are zero human trials, the single independent in-vivo replication failed to reproduce the BDNF benefit, and almost all the positive work comes from the inventor, who co-founded the company commercializing it. Read the full breakdown →
The prediction game
Where does P21 (P021) go in 12 months?
Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Be the first scout on record for P21 (P021). Permanent credit on this page, plus points when your call resolves.
One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
Same as above — one verification covers all your entries here.
For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.